Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Liabilities and Shareholders Equity (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $686.6 million in Q3 2022.

  • For Q3 2022, Liabilities and Shareholders Equity fell 18.6% year-over-year to $686.6 million; the TTM value through Dec 2022 reached $2.1 billion, down 36.97%, while the annual FY2021 figure was $772.9 million, 10.51% down from the prior year.
  • Liabilities and Shareholders Equity reached $686.6 million in Q3 2022 per AVIR's latest filing, down from $694.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $871.5 million in Q2 2021 and bottomed at $110.1 million in Q3 2020.
  • Average Liabilities and Shareholders Equity over 3 years is $711.2 million, with a median of $772.9 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 666.08% in 2021, then dropped 20.33% in 2022.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $863.6 million in 2020, then dropped by 10.51% to $772.9 million in 2021, then decreased by 11.17% to $686.6 million in 2022.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $686.6 million in Q3 2022, $694.3 million in Q2 2022, and $717.2 million in Q1 2022.